Don’t miss a thing by getting the Daily Star’s biggest headlines straight to your inbox!
A new Covid pill developed by Pfizer has been approved in the UK for people at high risk of developing severe symptoms from the virus.
Paxlovid, an oral tablet created by Pfizer Inc, is designed for over 18s with mild to moderate illness who are susceptible to contracting coronavirus.
A rigorous review of its safety, quality and effectiveness has been carried out.
Dr June Raine, Medicines and Healthcare products Regulatory Agency Chief Executive, said: “Today we have given our regulatory approval for Paxlovid, a COVID-19 treatment found to cut COVID-19 related hospitalisations and deaths by 89% when taken within three days of the start of symptoms.
“We now have a further antiviral medicine for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously.
"This means it can be administered outside a hospital setting, before COVID-19 has progressed to a severe stage."
The tablet is an antiviral medicine with ingredients that prevent the virus from multiplying, keeping levels low and helping the body to overcome the viral infection.
It must be taken twice a day for five days.
It is designed for patients aged 18 and over with mild to moderate illness who are susceptible to contracting coronavirus.
Health and Social Care Secretary Sajid Javid, said: “The UK has been a world leader at finding and rolling out COVID-19 treatments to patients.
Stay up to date with all the latest Daily Star news by signing up to one of our free newsletters here.
"This is further proved by the MHRA being one of the first in the world to approve this life-saving antiviral.
“We are also leading the whole of Europe in the number of antivirals we’ve bought per person – with over 2.75 million courses of this antiviral secured for NHS patients by the Antivirals Taskforce.
“The booster campaign, testing and antiviral defences ensure our country is in the strongest possible position to deal with the threat posed by Omicron as we head into the new year."
Source: Read Full Article